#1 Clinical Trials Search in Europe

3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide

This article discusses ongoing clinical trials investigating the use of CGT9486, also known as bezuclastinib, for treating gastrointestinal stromal tumors (GIST) and systemic mastocytosis. CGT9486 is a small molecule tyrosine kinase inhibitor that targets certain forms of mutated KIT kinase. The trials aim to evaluate the safety, efficacy, and optimal dosing of CGT9486 in patients with these conditions.

Table of Contents

Introduction

CGT9486, also known as bezuclastinib, is an experimental medication currently being studied for the treatment of certain rare cancers and blood disorders. This article will provide an overview of CGT9486, its potential uses, and the ongoing clinical trials evaluating its safety and effectiveness.

What is CGT9486 (Bezuclastinib)?

CGT9486 (bezuclastinib) is a new drug being developed by Cogent Biosciences. It is classified as a small molecule tyrosine kinase inhibitor that specifically targets a protein called KIT[1]. CGT9486 is taken orally in the form of tablets.

Conditions Treated

CGT9486 is being studied for the treatment of two main conditions:

  1. Gastrointestinal Stromal Tumors (GIST): These are rare tumors that occur in the digestive tract, most commonly in the stomach or small intestine[1].
  2. Systemic Mastocytosis (SM): This is a rare blood disorder characterized by an excessive number of mast cells (a type of white blood cell) accumulating in various tissues of the body[2]. There are two main types being studied:
    • Nonadvanced Systemic Mastocytosis (NonAdvSM): Including indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis (SSM)
    • Advanced Systemic Mastocytosis (AdvSM): Including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)

How It Works

CGT9486 works by targeting and inhibiting a specific protein called KIT, particularly mutated forms of KIT that are often found in GIST and systemic mastocytosis. By blocking the activity of these mutated KIT proteins, CGT9486 may help to slow down or stop the growth of cancer cells and abnormal mast cells[1].

Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of CGT9486:

  1. PEAK Study (Phase 3): This trial is comparing CGT9486 in combination with sunitinib versus sunitinib alone in patients with advanced gastrointestinal stromal tumors[1].
  2. SUMMIT Study (Phase 2): This trial is evaluating CGT9486 versus placebo in patients with nonadvanced systemic mastocytosis[2].
  3. Advanced Systemic Mastocytosis Study (Phase 2): This trial is assessing CGT9486 in patients with advanced forms of systemic mastocytosis[3].

Potential Benefits

Based on the ongoing clinical trials, CGT9486 may offer several potential benefits:

  • Improved progression-free survival in patients with gastrointestinal stromal tumors[1]
  • Reduction in symptoms associated with systemic mastocytosis, such as fatigue, skin lesions, and gastrointestinal issues[2]
  • Decrease in serum tryptase levels, which is a marker of mast cell activity[2]
  • Potential for improved quality of life for patients with these rare conditions[2]

Possible Side Effects

As CGT9486 is still in clinical trials, the full range of potential side effects is not yet known. However, some possible side effects based on similar drugs and the nature of the conditions being treated may include:

  • Gastrointestinal issues (nausea, diarrhea, vomiting)
  • Fatigue
  • Changes in blood cell counts
  • Skin reactions
  • Liver function abnormalities

It’s important to note that the clinical trials are closely monitoring for any adverse events to ensure patient safety[1][2][3].

Conclusion

CGT9486 (bezuclastinib) is a promising new medication being studied for the treatment of gastrointestinal stromal tumors and systemic mastocytosis. While still in clinical trials, it shows potential in addressing these rare and challenging conditions. Patients interested in learning more about CGT9486 should consult with their healthcare providers and consider participating in clinical trials if eligible.

Trial Name Condition Phase Primary Endpoints Key Eligibility Criteria
PEAK Gastrointestinal Stromal Tumors (GIST) Phase 3 Progression-free survival (PFS) Locally advanced, metastatic, or unresectable GIST; Prior imatinib treatment
SUMMIT Nonadvanced Systemic Mastocytosis Phase 2 Change in MS2D2 score; Safety assessments Indolent or smoldering systemic mastocytosis; Moderate-to-severe symptoms
Unnamed Advanced Systemic Mastocytosis Phase 2 Overall response rate (ORR); Safety assessments Aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm, or mast cell leukemia

FAQ

  • What is CGT9486? CGT9486, also known as bezuclastinib, is a small molecule tyrosine kinase inhibitor that targets certain forms of mutated KIT kinase. It is being studied as a potential treatment for gastrointestinal stromal tumors (GIST) and systemic mastocytosis.
  • What conditions are being studied in these clinical trials? The clinical trials are investigating CGT9486 for the treatment of gastrointestinal stromal tumors (GIST), nonadvanced systemic mastocytosis, and advanced systemic mastocytosis.
  • What are the main objectives of these trials? The main objectives of these trials include determining the safety, efficacy, and optimal dosing of CGT9486 in patients with GIST and systemic mastocytosis. They also aim to evaluate the drug's effects on disease symptoms, biomarkers, and quality of life.
  • How is CGT9486 administered? CGT9486 is administered orally in tablet form. The dosage and frequency may vary depending on the specific trial and condition being studied.
  • What are some of the key endpoints being measured in these trials? Key endpoints include overall response rate (ORR), progression-free survival (PFS), overall survival (OS), changes in serum tryptase levels, KIT D816V mutation allele burden, and various safety assessments such as adverse events and laboratory results.

Ongoing Clinical Trials on 3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide

  • Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

    Not recruiting

    2 1 1
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +3

  • Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Czechia Denmark France Germany Hungary Italy +5

  • Study on the Safety and Effectiveness of CGT9486 for Patients with Nonadvanced Systemic Mastocytosis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +6

Glossary

  • Gastrointestinal Stromal Tumor (GIST): A type of cancer that occurs in the digestive system, most commonly in the stomach or small intestine. GISTs are soft tissue sarcomas that can be caused by mutations in genes such as KIT.
  • Systemic Mastocytosis: A rare condition characterized by an excessive number of mast cells accumulating in various tissues of the body. It can be classified as nonadvanced (indolent or smoldering) or advanced forms.
  • Tyrosine Kinase Inhibitor: A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cell signaling and growth. In cancer treatment, these drugs can help stop the growth and spread of cancer cells.
  • KIT Kinase: An enzyme that plays a role in cell signaling and is often mutated in certain types of cancer, including GIST and systemic mastocytosis. CGT9486 is designed to target mutated forms of KIT kinase.
  • Serum Tryptase: An enzyme released by mast cells. Elevated levels of serum tryptase can indicate increased mast cell activity or number, which is often seen in systemic mastocytosis.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment. It is a measure of treatment effectiveness in clinical trials.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse. It is an important measure of treatment efficacy in cancer trials.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities. It ranges from 0 (fully active) to 5 (death).

References

  1. http://clinicaltrials.eu/trial/study-of-cgt9486-and-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumors/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cgt9486-for-patients-with-nonadvanced-systemic-mastocytosis/
  3. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bezuclastinib-for-patients-with-advanced-systemic-mastocytosis/